The global asthma therapeutics market size reached USD 18.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 22.1 Billion by 2033, exhibiting a growth rate (CAGR) of 1.8% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 18.8 Billion |
Market Forecast in 2033
|
USD 22.1 Billion |
Market Growth Rate (2025-2033) | 1.8% |
Asthma therapeutics refer to various pharmaceutical drugs that are used for the treatment of asthma. Asthma is usually triggered by indoor and outdoor causative agents, including pollution, allergens and dust. These therapeutics are usually bronchodilators and anti-inflammatory drugs, which include corticosteroids, long-acting beta-agonists (LABA), methylxanthine, immunomodulators and leukotriene modifiers. A number of combination therapy drugs are also used that can be inhaled, injected, or orally administered. These drugs expand the passageway into the lungs and enable the movement of air to improve breathing. They also aid in clearing mucus from the lungs that gets coughed out with ease.
The increasing prevalence of asthma and other respiratory disorders, along with improvements in the diagnostic technologies, is one of the key factors driving the growth of the market. Furthermore, rising awareness among the masses regarding the availability of effective asthma therapeutics is also providing driving the market growth. For instance, asthmatic patients are primarily treated with inhaled corticosteroids and patients with advanced conditions or persistent asthma are treated with target-specific drugs. There is also an extensive demand for monoclonal antibodies (mAbs) that block immunoglobulin E and specific cytokines. The development of combination therapies for the treatment of respiratory diseases is acting as another growth-inducing factor. Increasing healthcare expenditures, extensive research, and development (R&D) activities in the field of medical sciences and improvements in the healthcare infrastructure are some of the other factors that are expected to drive the market further.
IMARC Group provides an analysis of the key trends in each segment of the global asthma therapeutics market report, along with forecasts at the global, regional and country levels from 2025-2033. Our report has categorized the market based on drug class, product type, treatment type and route of administration.
Breakup by Drug Class:
Breakup by Product Type:
Breakup by Treatment Type:
Breakup by Route of Administration:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being AstraZeneca PLC, Abbott Laboratories, Amgen Inc., Biogen Inc., Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck Sharp & Dohme Corp., Novartis International AG, Sunovion Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Drug Class, Product Type, Treatment Type, Route of Administration, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | AstraZeneca PLC, Abbott Laboratories, Amgen Inc., Biogen Inc., Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck Sharp & Dohme Corp., Novartis International AG, Sunovion Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global asthma therapeutics market was valued at USD 18.8 Billion in 2024.
We expect the global asthma therapeutics market to exhibit a CAGR of 1.8% during 2025-2033.
The increasing prevalence of asthma, along with the continuous improvements in the diagnostic technologies, are primarily driving the global asthma therapeutics market.
The sudden outbreak of the COVID-19 pandemic has led to the rising adoption of asthma therapeutics for treating asthma, as it is a major side-effect of the coronavirus infection.
Based on the drug class, the global asthma therapeutics market has been segmented into anti-inflammatory drugs, bronchodilators, and combination therapies. Currently, combination therapies hold
the majority of the total market share.
Based on the product type, the global asthma therapeutics market can be segregated into inhalers and nebulizers, where inhalers currently exhibit a clear dominance in the market.
Based on the treatment type, the global asthma therapeutics market has been bifurcated into quick- relief medications and long-term asthma control medications. Currently, long-term asthma control medications account for the majority of the global market share.
Based on the route of administration, the global asthma therapeutics market can be divided into inhalation, oral, and parenteral. Among these, inhalation holds the largest market share.
On a regional level, the market has been classified into North America, Asia Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global asthma therapeutics market include AstraZeneca PLC, Abbott Laboratories, Amgen Inc., Biogen Inc., Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck Sharp & Dohme Corp., Novartis International AG, Sunovion Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd.